Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Shreekant Parasuraman"'
Autor:
Kelley Myers, Jonathan I. Silverberg, Shreekant Parasuraman, Anna Pierce, Lawrence F. Eichenfield, Christine Poulos
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Study purpose: New treatments for atopic dermatitis (AD) are emerging; however, little is known about the treatment preferences of patients with mild-to-moderate AD. To measure patients’ preferences, a cross-sectional, web-based discrete choice exp
Externí odkaz:
https://doaj.org/article/e9dbc6a1d2b6460da99b9dd231d24451
Autor:
Tsewang Tashi, Jingbo Yu, Shivani Pandya, Christopher Dieyi, Robyn Scherber, Shreekant Parasuraman
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Primary myelofibrosis [PMF] is a myeloproliferative neoplasm associated with reduced overall survival (OS). Management strategies for PMF have evolved over the last two decades, including approval of ruxolitinib as the first Janus
Externí odkaz:
https://doaj.org/article/20afc45271924e2b9dc3708d2146874e
Publikováno v:
PLoS ONE, Vol 15, Iss 12, p e0243562 (2020)
BackgroundRecruitment of individuals with rare diseases for studies of real-world patient-reported outcomes is limited by small base populations. Myeloproliferative neoplasms (MPNs) are a group of rare, chronic, hematologic malignancies. In this stud
Externí odkaz:
https://doaj.org/article/ef11d42e08ad4a81a28e612ceb7fe7f3
Autor:
Dilan Paranagama, Philomena Colucci, Kristin A. Evans, Machaon Bonafede, Shreekant Parasuraman
Publikováno v:
Experimental Hematology & Oncology, Vol 7, Iss 1, Pp 1-6 (2018)
Abstract Background Patients with polycythemia vera (PV) have a higher mortality risk compared with the general population, primarily driven by cardiovascular disease, thrombotic events (TEs), and hematologic transformations. The goal of risk-adapted
Externí odkaz:
https://doaj.org/article/7893ab59707349769959d1b10311ef16
Autor:
Shreekant Parasuraman, Jingbo Yu, Dilan Paranagama, Sulena Shrestha, Li Wang, Onur Baser, Robyn Scherber
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Polycythemia vera (PV) is a myeloproliferative neoplasm associated with increased thrombotic and cardiovascular risk, which are key contributors to patient morbidity and mortality. The Veterans Health Administration (VHA) is the l
Externí odkaz:
https://doaj.org/article/d4c123255d1b493b9949bd44b6a8b92d
Autor:
Jingbo Yu, Shreekant Parasuraman, Dilan Paranagama, Andrew Bai, Ahmad Naim, David Dubinski, Ruben Mesa
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background Patients with the myeloproliferative neoplasms (MPNs) myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are at increased risk for thrombotic and cardiovascular events and experience a variety of burden
Externí odkaz:
https://doaj.org/article/2b62baca57b04bb0a8d2443aa08d499a
Publikováno v:
Journal of Medical Economics. 26:454-462
Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA. To assess productivity loss, associated indirect costs,
Autor:
Philomena Colucci, Jingbo Yu, Jonathan Kish, Dilan Paranagama, Shreekant Parasuraman, Kevin C Lord, Ivy Altomare
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e915-e921
Background Polycythemia vera (PV) is a myeloproliferative neoplasm affecting >100,000 people in the United States annually. Patients (pts) with PV are at risk for thromboembolic events (TEs), premature death, and high symptom burden. Hydroxyurea (HU)
Autor:
Jingbo Yu, Shreekant Parasuraman, Ann Xi, Srdan Verstovsek, Anne Shah, Shambhavi Kumar, Claire N. Harrison
Publikováno v:
Annals of Hematology
The Janus kinase inhibitor ruxolitinib is approved for the treatment of myelofibrosis (MF) and improved overall survival (OS) versus control therapy in the phase 3 COMFORT trials. The aim of this retrospective analysis was to examine the real-world i
Autor:
Shreekant Parasuraman, Anna Teschemaker, Jonathan K. Kish, Kristin M. Savill, Philomena Colucci
Publikováno v:
Blood. 140:6854-6855